Artificial Intelligence
April 23–25, 2018
Boston, MA • United States

Allison Kean, MD

  • CV Therapeutic Area Lead, Global Business Development, Pfizer

Dr. Allison Kean is a board certified cardiologist who currently serves as the Therapeutic Area Lead for Cardiovascular Disease and Women’s/Men’s Health for Global Business Development at Pfizer.

Following training and board-certification in internal medicine and cardiology at Northwestern University, Dr. Kean joined the clinical faculty at the UCLA School of Medicine in 2003. With a subspecialty focus on heart failure/transplant and non-invasive cardiac imaging, she has remained active in patient care, medical education, and clinical research. She joined Pfizer in 2007 where she supported the in-line pharmaceutical portfolio as well as research pipeline with contributions to the Lipitor and Eliquis programs amongst others. She continues to support scientific due diligence, Cardiovascular Safety issues, and business development opportunities across the company including Pfizer Venture Investments. Dr. Kean maintains her academic appointment and privileges at UCLA Medical Center where she is as an Assistant Clinical Professor of Medicine/Cardiology and sees patients as an attending physician at the UCLA Advanced Heart Failure and Heart Transplant Center. She is a Fellow of the American Heart Association, Fellow of the American College of Cardiology, and serves as the founding faculty advisor to the WomenHeart group in Los Angeles, a national advocacy and support group for women living with heart disease. She currently serves on the Harvard Kennedy School Women’s Leadership Board and previously served on the Los Angeles Board of the American Heart Association (AHA).

Dr. Kean graduated from the University of Virginia as a Thomas Jefferson Scholar. She completed medical school at the Medical College of Pennsylvania/Hahnemann School of Medicine. Following medical school, she completed an internal medicine residency and cardiology fellowship at Northwestern University School of Medicine. She received board certification in both Internal Medicine and Cardiovascular Disease followed by re-certification in Cardiovascular Disease in 2014.

This speaker appears at this event: